Description: Given the rise in interest rates during 2022, explore the implications of increasing rates on FA and FIA business by looking at industry experience for FA and FIA products for 2022 compared to earlier years. Additionally, come walk through partial withdrawals, GLWB utilization, mortality and what to expect as interest rate volatility continues. You'll also discover how direct writers and reinsurers are handing the in-force management aspects of these products in the uncertain and volatile economic periods. Key learning outcomes include: - Understand the impact of rising rates on dynamic lapse for FA and FIA products - Explanation ofin-force management actions that are being taken in the current interest rate environment - Be informed of current trends in GLWB utilization

Description: This panel discussion will focus on how companies have been able to take advantage of the new US GAAP requirements, to develop and refine other performance indicators that provide additional insights into their business.

Description: Discuss a comparison of the U.S. general and insured population mortality experience and how COVID-19 and non-COVID-19 excess deaths impacted the populations differently. Discover the population mortality experience in the UK with a focus on the recent emergence of excess deaths for non-COVID causes. The long-term implications on the insured population will also be explored. Wrap up with a discussion of different conditions of long COVID, including organ impairments.

Description: Explore the value and cost of prescription drugs, how they should be defined and measured and the effects various stakeholders in the pharmacy ecosystem can have on these factors in the latest webcast. You'll investigate the impact of coverage, formulary and rebate negotiations and related benefit design. Find out how actuaries can answer questions related to the prescription drug industry, in addition to improving the access, quality and affordability of prescription drugs in the United States. Join us for this webcast and come learn about value-based contract design, negotiations, implementation and administration for prescription drugs.

Description: This session will discuss the macro-economic impact (tariff/changing interest rate environment/government fiscal policy and etc.) on the insurance industry. We will relate this to the actuarial function such as corporate strategy/risk management/product pricing & marketing

Description: Recently, life insurers have seen a lot of change in their business model. Whether it be new accounting rules (e.g., long-duration targeted improvements [LDTI]) or new capital charges (e.g., structured equity tranche), companies are being forced to reconsider how they invest their assets. Today's session will help attendees understand how companies are using modelling software to help understand the impact of these changes on both their existing portfolio and potential changes that these new regulations may lead to. By attending, attendees will get a better understanding of: - How life insurers' asset allocation decisions are different than other financial companies (e.g., banks, pension funds, P&C companies) - How these changes may impact the risk vs. reward tradeoffs that life insurers' face - How these companies can use modelling software to help evaluate these potential impacts

Description: Attendees will learn how carriers and InsurTechs interact with private equity (PE), banks, and other investors who are increasingly interested in taking on traditional insurance risks. The introduction includes a review of recent large transactions, trends in InsurTech funding, and a primer on a typical transaction. There will also be a discussion amongst a panel of experts on the 'why' behind recent trends and future outlooks. Some specific questions we'll answer: Is this a good thing for the insurance industry? How are these trends impacted by interest rates? Where do actuaries fit in? How can a PE/bank investment be set up for success?

Description: Cost is a key outcome metric used by actuaries and others to determine the value of a benefit or program in health insurance. However, typically, costs assessed include only the direct costs of the program, not any indirect costs or savings, such as those associated with reduced spending on other services.

Description: The Part D program is funded through a variety of government subsidies and manufacturer discounts. The federal reinsurance, initially designed as protection from catastrophic spending, became a primary source of subsidies for the program. When the Inflation Reduction Act (IRA) is fully implemented in 2025, the funding of Part D will realign to its original intent.

Description: Presenters will discuss difficulties within the new NAIC ESG, such as how the model deals with interest rate flooring and its treatment of the linkage between equity and treasury bond returns. They will also discuss the documentation and governance process surrounding the new NAIC ESG.